[Articles] Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial

Treatment with the direct-acting oral anticoagulant apixaban in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack led to a 7% absolute risk reduction in stroke or systemic embolism over 3·5 years, compared with a 1% absolute risk reduction for individuals without a previous history of stroke or transient ischaemic… Continue reading [Articles] Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial

[Comment] Anticoagulation for patients with device-detected atrial fibrillation and a history of stroke

In people with atrial fibrillation, a history of stroke is associated with increased risk of future cerebrovascular events compared with individuals without a history of stroke. Furthermore, people with atrial fibrillation and a history of stroke are more likely to benefit from oral anticoagulation than are those without a history of stroke. However, the effect… Continue reading [Comment] Anticoagulation for patients with device-detected atrial fibrillation and a history of stroke